scholarly journals Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans

2021 ◽  
Vol 7 ◽  
Author(s):  
Irene Lucía Ennis ◽  
Néstor Gustavo Pérez
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mineralocorticoid Receptor ◽  
Clinical Evidence ◽  
Physiological Role ◽  
Underlying Mechanism ◽  
Current Evidence ◽  
Cardiac Diseases ◽  
Myocardial Stretch ◽  
Consequent Increase

Current evidence reveals that cardiac mineralocorticoid receptor (MR) activation following myocardial stretch plays an important physiological role in adapting developed force to sudden changes in hemodynamic conditions. Its underlying mechanism involves a previously unknown nongenomic effect of the MR that triggers redox-mediated Na+/H+ exchanger (NHE1) activation, intracellular Na+ accumulation, and a consequent increase in Ca2+ transient amplitude through reverse Na+/Ca2+ exchange. However, clinical evidence assigns a detrimental role to MR activation in the pathogenesis of severe cardiac diseases such as congestive heart failure. This mini review is meant to present and briefly discuss some recent discoveries about locally triggered cardiac MR signals with the objective of shedding some light on its physiological but potentially pathological consequences in the heart.

scholarly journals Mineralocorticoid Receptor Is Overexpressed in Cardiomyocytes of Patients With Congestive Heart Failure

2005 ◽  
Vol 11 (1) ◽  
pp. 12-16 ◽  
Author(s):  
Masahiro Yoshida ◽  
Jun Ma ◽  
Tsutomu Tomita ◽  
Norihiro Morikawa ◽  
Nobuyoshi Tanaka ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Mineralocorticoid Receptor

Impact of stroke on heart function

ESC CardioMed ◽  
2018 ◽  
pp. 954-957
Author(s):  
Christoph Kleinschnitz
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Congestive Heart Failure ◽  
Heart Disease ◽  
Neurological Disease ◽  
Heart Function ◽  
Population Based ◽  
Cardiac Diseases ◽  
Possible Cause

Much emphasis has been placed on the heart as a possible cause of neurological disease. Cardiac diseases, such as atrial fibrillation, valvular heart disease, or congestive heart failure are well-established, important risk factors for ischaemic stroke. Within population-based studies, about 30% of ischaemic strokes are caused by cardiac diseases.

scholarly journals Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?

2014 ◽  
Vol 20 (3) ◽  
pp. 283-290 ◽  
Author(s):  
Amirali Masoumi ◽  
Fernando Ortiz ◽  
Jai Radhakrishnan ◽  
Robert W. Schrier ◽  
Paolo C. Colombo
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Liver Failure ◽  
Mineralocorticoid Receptor ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists

Ca2+ Sparks in Cardiac Muscle: Is There Life Without Them?

Physiology ◽  
1999 ◽  
Vol 14 (4) ◽  
pp. 129-134
Author(s):  
Ernst Niggli
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cardiac Muscle ◽  
Cardiac Diseases ◽  
Signaling Events ◽  
Near Future

The discovery of elementary Ca2+ signaling events, the Ca2+ sparks, has profoundly changed our view of cardiac Ca2+ signaling and, in particular, excitationcontraction coupling. In addition, a partial disruption of cardiac Ca2+ signaling may be important in clinical cardiac conditions such as congestive heart failure. Understanding cardiac diseases on the cellular and molecular levels may provide a key to new pharmacological strategies in the near future.

The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction

2019 ◽  
Vol 24 (46) ◽  
pp. 5517-5524 ◽  
Author(s):  
Vasilios Papademetriou ◽  
Maria Toumpourleka ◽  
Konstantinos P. Imprialos ◽  
Sofia Alataki ◽  
Alexandros Manafis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Mineralocorticoid Receptor ◽  
Morbidity And Mortality ◽  
Current Evidence ◽  
Mineralocorticoid Receptor Antagonists ◽  
Receptor Antagonists ◽  
Level Of Evidence ◽  
Reduced Ejection Fraction

Background: Heart failure (HF) is a worldwide modern epidemic, associated with significant morbidity and mortality. Several causes have been identified for the syndrome, most of which share common pathophysiologic pathways, including neurohormonal activation. Central to the latter lies activation of the reninangiotensin- aldosterone system, and its effects on cardiovascular disease progression. Objectives: The aim of this review is to summarize the pathophysiology of aldosterone and the effects of its blockage in the failing heart, as well as to provide state-of-the-art evidence, and address future perspectives regarding the use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction. Method: Literature was reviewed for studies that assess the pathophysiology of aldosterone in HF with reduced ejection fraction (HFrEF), and the effects of mineralocorticoid receptor antagonists (MRAs) in this condition. Results: Several major society guidelines have synthesized the available evidence on HFrEF management, and drugs that block the renin-angiotensin-aldosterone system at different levels continue to form the key component of standard of care for these patients. Mineralocorticoid receptor antagonists are an important part of HFrEF pharmacologic treatment, and their use is supported by a high level of evidence studies. This class of drugs demonstrated significant benefits for morbidity and mortality, across the spectrum oh HFrEF, including patients after acute myocardial infarction. Conclusion: Current evidence supports the central role of aldosterone in HFrEF progression, and the significant benefits on outcomes with the use of MRAs.

scholarly journals Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database

2021 ◽  
Vol 12 ◽  
pp. 215013272110292
Author(s):  
Anasua Deb ◽  
John Abdelmalek ◽  
Kenneth Iwuji ◽  
Kenneth Nugent
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Adverse Events ◽  
Myocardial Injury ◽  
Reporting System ◽  
Clinical Course ◽  
Current Evidence ◽  
Acute Myocardial Injury ◽  
Control And Prevention ◽  
Mass Expansion

COVID-19 vaccination related adverse events is an evolving field. Here we present a case of acute myocardial injury that developed as a result of an acute immune response following the second dose of COVID-19 vaccination (Moderna) in a 67-year-old man who presented in acute congestive heart failure. His clinical course improved over 3 days. Review of the Vaccine Adverse Events Reporting System (VAERS) in the Centers for Disease Control and Prevention websites identified 37 vaccine recipients who developed myocarditis as an adverse event following COVID-19 vaccination. With the mass expansion of COVID-19 vaccine administration, physicians need to be vigilant about the possibility of new adverse events.

Sign in / Sign up

Export Citation Format

Share Document